Search results for: psoriatic arthritis

Insight into the FDA Approval of Ustekinumab Biosimilar

Michele B. Kaufman, PharmD, BCGP | December 14, 2023

In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.

From Basic Science to Clinical Treatments: An Update on PsA

Jason Liebowitz, MD, FACR | November 16, 2023

Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.

FDA Approves Ustekinumab for Children with PsA

Michele B. Kaufman, PharmD, BCGP | November 7, 2022

After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.

PsA Trial Design Can Improve Patient Safety, Outcomes

Vanessa Caceres | June 15, 2022

For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.

European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease

Michele B. Kaufman, PharmD, BCGP | June 2, 2022

In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.

FDA Approves Risankizumab-rzaa for PsA

Michele B. Kaufman, PharmD, BCGP | April 20, 2022

Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.

How Do Axial SpA & PsA with Axial Involvement Differ?

Samantha C. Shapiro, MD | February 2, 2022

The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.

The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice

Mary Beth Nierengarten | December 2, 2021

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Reproductive Health & PsA: New ACR Training Program Enhances Provider Education

Mary Beth Nierengarten | November 23, 2021

The ACR has developed educational materials for healthcare providers to use to discuss reproductive health and contraception with their patients with psoriatic arthritis.

Guselkumab Promising in Patients with PsA

Michele B. Kaufman, PharmD, BCGP | October 7, 2021

Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).